In the claims:

1. (original) A compound according to the formula:

$$Z \xrightarrow{N \atop H} OR$$

where X is selected from the group consisting of R^a , R^b , R^c , R^d , R^e , R^f and R^g ;

R^a is

where R1 is an isobutylene group;

Rb is

where R^2 and R^3 are independently a C_1 - C_5 linear or branched-chain alkyl or alkene group;

R^c is

where R² is the same as above;

R^d is

where R² is the same as above and wherein said AR

group is a phenyl, naphthyl, para or ortho substituted biphenyl group;

 R^e is 4 is a C_1 - C_5 linear or branch-chained alkyl or alkene group, allyl or homoallyl group and R^5 is a C_1 - C_5 linear or branch-chained alkyl or alkene group;

, where R² and R³ are the same

$$R^{f}$$
 is

as is set forth above,

$$R^g$$
 is R^g where R^g is the same as is

set forth above;


Z is a C₁-C₁₂ alkyl or alkylene group, or a group according to the structure

wherein each of said groups may be optionally substituted with one or more halogen groups;

R is H or a C₁-C₁₈ alkyl group; and

pharmaceutically acceptable salts, anomers, solvates and polymorphs, thereof.

2. (original) The compound according to claim 1 wherein said formula is:



- 3. (original)The compound according to claim 2 wherein X is R^d , R^e or R^f .
- 4. (currently amended) The compound according to any of claims 1-3- claim 1 wherein R² or R⁴ is isobutenyl.
- 5. (currently amended) The compound according to any of claims 1-4 claim 1 where X is R^a.
- 6. (currently amended) The compound according to any of claims 1-4 claim 1 where X is R^b.
- 7. (currently amended) The compound according to any of claims 1-4 claim 1 where X is R^c.
- 8. (currently amended) The compound according to any of claims 1-4 claim 1 where X is R^d .
- 9. (currently amended) The compound according to any of claims 1-4 claim 1 where X is Re.
- 10. (currently amended) The compound according to any of claims 1-4 claim 1 where X is R^f .
- 11. (currently amended) The compound according to any of claims 1-4 claim 1 where X is R^g .
- 12. (currently amended) The compound according to any of claims 1-11 claim 1 where R^1 , R^2 , R^3 , R^4 or R^5 is an isobutenyl group.
- 13. (currently amended) The compound according to any of claims 1-12 claim 1 wherein Z is CH3.
- 14. (currently amended) The compound according to any of claims 1-12 claim 1 wherein Z is a group according to the structure:

wherein each of said groups is optionally substituted with one or two fluorine groups.

- 15. (currently amended) The compound according to any of claims 1-12 and 14 claim 1 wherein Z is a biphenyl group.
- 16. (currently amended) The compound according to any of claims 1-15 claim 1 wherein R is H.
- 17. (original) A pharmaceutically acceptable salt of the compound according to claim14.
- 18. (currently amended) The compound according to any of claims 1, 2, 3, 4 and 8 claim 1

wherein AR is substituted with 1 or 2 fluorine groups.

, optionally

- 19. (original) The compound according to claim 18 wherein AR is
- 20. (currently amended) The compound according to any of claims 1-14 and 17-19 claim 1 wherein R is a C_1 - C_{18} alkyl group.
- 21. (currently amended) The compound according to any of claims 1-20 claim 1 wherein R^2 or R^4 is isobutenyl.
- 22. (currently amended) A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1-21 claim 1 optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
- 23. (currently amended) A method for treating neoplasia in a patient in need thereof comprising administering to said patient an effective amount of a compound according to any of claims 1-22 claim 1.

- 24. (original) The method according to claim 23 wherein said neoplasia is a tumor.
- 25. (original) The method according to claim 24 wherein said tumor is cancerous.
- 25. (cancelled).
- 26. (currently amended) A method for treating a patient in need thereof for a disease or condition selected from the group consisting of hyperproliferative cell growth, restenosis following cardiovascular surgery, hyperplasia and chronic inflammatory diseases comprising administering to said patient suffering from said disease an effective amount of a compound according to any of claims 1-21 claim 1.
- 27. (original) The method according to claim 26 wherein said hyperproliferative cell growth disease or condition is hyperkeratosis, keratoderma, lichen, planus, psoriasis, warts or blisters.
- 28. (original) The method according to claim 27 wherein said hyperkeratosis is ichthyosis.
- 29. (currently amended) The method according to claim 26 or 27 wherein said hyproliferative cell growth disease or condition is psoriasis.
- 30. (currently amended) The method according to claim 27 wherein said warts are genital warts.
- 31. (original) The method according to claim 26 wherein said hyperplasia is cystic hyperplasia, nodular hyperplasia of the prostate or renal hyperplasia.
- 32. (original) The method according to claim 31 wherein said cystic hyperplasia is cystic hyperplasia of the breast.
- 33. (currently amended) A method for treating chronic inflammatory disease comprising

administering to a patient in need of therapy an effective amount of a compound according any of claims 1-21. claim 1.

- 34. (original) The method according to claim 33 wherein said chronic inflammatory disease is rheumatoid arthritis or osteoarthritis.
- 35. (currently amended) A method of inhibiting isoprenylcysteine methyltransferase enzyme comprising exposing said enzyme to an effective amount of a compound according to any of elaims 1-21. claim 1.
- 36. (currently amended) A method of inhibiting isoprenyl cysteine methyltransferase enzyme in a patient in order to treat a disease or condition modulated by said enzyme comprising administering to said patient an effective amount of a compound according to any of claims 1-21-claim 1.
- 37-38. (cancelled).
- 39. (new) The method according to claim 23 wherein said neoplasia is a cancer of the stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/cns, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, melanoma, acute lymphocytic leukemia, acute mylogenous leukemia, Ewings Sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms Tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, melanoma or kidney.